ATOSSA THERAPEUTICS, INC. (ATOS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US04962H7044
ATOSSA THERAPEUTICS, INC. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -37.14 m USD |
| EBIT | -37.15 m USD |
| Net income | -34.77 m USD |
| Diluted EPS – continuing operations | -4.04 USD |
Full history since 2009, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About ATOSSA THERAPEUTICS, INC.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
More stocks
- Lument Finance Trust, Inc. (LFT)
- BuzzFeed, Inc. (BZFD)
- Western Uranium & Vanadium Corp. (WSTRF)
- Eva Live Inc (GOAI)
- Crisp Momentum Inc. (CRSF)
- Karbon-X Corp. (KARX)
- PetVivo Holdings, Inc. (PETV)
- BioInvent International AB (BINV.ST)
- Sun Pacific Holding Corp. (SNPW)
- SolarMax Technology, Inc. (SMXT)
- REED'S, INC. (REED)
- AYTU BIOPHARMA, INC (AYTU)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.